Andy Phillips is President and Chief Executive Officer of Aleksia Therapeutics, Inc. and Blossom Bioscience Ltd. Previously, he was Managing Director at Cormorant Asset Management, LP and Chief Financial Office of Helix Acquisition Corp. Before joining Cormorant, he was the President and Chief Executive Officer of C4 Therapeutics. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at The Broad Institute of MIT and Harvard. Previously, he was a Professor of Chemistry at Yale University and a Professor of Chemistry and Biochemistry at the University of Colorado. Andy holds Ph.D. and B.Sc. Hons. degrees in Chemistry and Biochemistry from the University of Canterbury (Christchurch, New Zealand).